Drug Profile
Research programme: analgesics - Cassava Sciences
Alternative Names: PTI-609Latest Information Update: 01 Apr 2019
Price :
$50
*
At a glance
- Originator Pain Therapeutics
- Developer Cassava Sciences
- Class Opioid analgesics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arthritis; Pain
Most Recent Events
- 27 Mar 2019 Pain Therapeutics is now called Cassava Sciences
- 16 Jul 2016 No recent reports of development identified for preclinical development in Arthritis in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA (PO)